GI Dynamics Announces Change to Board of Directors
June 01 2017 - 5:41PM
Business Wire
GI Dynamics®, Inc. (ASX:GID), a medical device company that has
developed an innovative device to improve outcomes for patients
diagnosed with type 2 diabetes and obesity, announces today that
the board of directors has received the resignation of GI Dynamics
non-executive director Mike Carusi of Advanced Technology Ventures
(ATV) and Lightstone Ventures (LSV).
“Mike has served on the board of GI Dynamics since 2004, and we
thank him for his significant contributions and many years of
service,” said Dan Moore, chairman of the board.
“After more than a decade serving as a director, and in light of
my other numerous commitments with ATV and LSV, I have decided to
step down from the board of GI Dynamics,” said Carusi. “I wish the
team future success as the company advances to the next chapter. I
remain optimistic about the potential for EndoBarrier® as an
important treatment option for patients with type 2 diabetes and
obesity.”
About GI DynamicsGI Dynamics, Inc. (ASX:GID), is the
developer of EndoBarrier, the first endoscopically-delivered device
therapy approved for the treatment of type 2 diabetes and obesity.
EndoBarrier is not approved for sale in the United States and is
limited by federal law to investigational use only in the United
States. Founded in 2003, GI Dynamics is headquartered in Boston,
Massachusetts. For more information, please visit
www.gidynamics.com.
Forward-Looking StatementsThis announcement contains
forward-looking statements concerning the potential for EndoBarrier
as an important treatment option for patients with type 2 diabetes
and obesity. These forward-looking statements are based on GI
Dynamics management’s current estimates and expectations of future
events as of the date of this announcement. Furthermore, the
estimates are subject to several risks and uncertainties that could
cause actual results to differ materially and adversely from those
indicated in or implied by such forward-looking statements. These
risks and uncertainties include but are not limited to, risks
associated with obtaining funding from third parties; the
consequences of stopping the ENDO trial and the possibility that
future clinical trials will not be successful or confirm earlier
results; the timing and costs of clinical trials; the timing of
regulatory submissions; the timing, receipt and maintenance of
regulatory approvals; the timing and amount of other expenses; the
timing and extent of third-party reimbursement; risks associated
with commercial product sales, including product performance,
competition, market acceptance of products, intellectual-property
risk; risks related to excess inventory; and risks related to
assumptions regarding the size of the available market, the
benefits of our products, product pricing, timing of product
launches, future financial results and other factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. Given these uncertainties, one should not
place undue reliance on these forward-looking statements. We do not
assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information
or future events or otherwise, unless we are required to do so by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170601006704/en/
GI Dynamics, Inc.Investor RelationsUnited States:Janell
Shields, +1-781-357-3280Investor
Relationsinvestor@gidynamics.comorMedia RelationsUnited
States:Nicole Franklin, +1-617-657-1312nfranklin@jpa.com
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2023 to Apr 2024